Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + Bortezomib + Dexamethasone in Japanese RRMM
NCT02497378Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2015
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs). Started Jul 2015; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02497378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02497378.